About This Fund
Seroba's Fund IV is focused on making early-stage investments in life sciences companies, particularly in Western Europe and selectively in North America, with a primary emphasis on biotech. The fund has already made investments in five companies located in Ireland, Italy, Germany, and the Netherlands. The target investments for the fund include innovative treatments addressing major unmet medical needs. The fund has attracted support from existing investors and new investors, including CDP Venture Capital and a US corporate, as well as family offices. The fund has a target of up to 12 investments and has a strong focus on backing cutting-edge biotech and medtech innovation that will transform the treatment of patients and address unmet medical needs.
As of Feb. 2024, the fund has invested in 5 companies: Perfuze, Sibylla Biotech, Deciphex, Complement Therapeutics and Artica Therapeutics. These companies are developing novel treatments addressing major unmet medical needs.